Brachytherapy And Gyn Malignancy

3,779 views

Published on

Published in: Health & Medicine
0 Comments
4 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
3,779
On SlideShare
0
From Embeds
0
Number of Embeds
23
Actions
Shares
0
Downloads
262
Comments
0
Likes
4
Embeds 0
No embeds

No notes for slide

Brachytherapy And Gyn Malignancy

  1. 1. Brachytherapy and GYN malignancy
  2. 2. Brachytherapy <ul><li>Brachytherapy ( brachy , from the Greek for “short distance”) consists of placing sealed radioactive sources close to or contact with the target tissue. </li></ul><ul><li>Interstitial, intracavity, or transluminal approach. </li></ul><ul><li>Temporary, or permanent implant. </li></ul><ul><li>Low or high dose rate. </li></ul>
  3. 3. Introduction <ul><li>Discovery in 1898 </li></ul><ul><li>Short distance (cm) </li></ul><ul><li>High radiation dose can be delivered locally to the tumor with rapid dose fall-off in the surrounding normal tissue </li></ul>
  4. 5. Radioactive sources
  5. 6. Radioactive sources Radium-226 <ul><li>Average energy 0.83Mev (0.5mm of platinum) </li></ul><ul><li>A filtration of at least 0.5mm platinum is sufficient to absorb all the α particles and most of the β particles emitted by the radium and its daughter products. </li></ul><ul><li>Half life ~ 1600 years </li></ul><ul><li>It was loaded into cells about 1cm long and 1mm in diameter . </li></ul><ul><li>Radium sources are manufactured as needles or tubes in a variety of lengths and activities </li></ul>
  6. 7. Radioactive sources Cesium-137 <ul><li>Substitute for radium in both interstitial and intracavitary brachytherapy </li></ul><ul><li>Energy 0.662Mev nearly the same penetrating power as radium </li></ul><ul><li>Half life 30 years (clinically used 7 years without replacement) It was doubly encapsulated in stainless-steel needles and tubes. </li></ul>
  7. 9. Radioactive sources Cobalt-60 <ul><li>High specific activity </li></ul><ul><li>Small sources required for some special applicators </li></ul><ul><li>More expensive than 137 Cs and short half life (5.26 years) </li></ul><ul><li>The sources can be used to replace 226 Ra in intracavitary application </li></ul>
  8. 10. Radioactive sources Iridium-192 <ul><li>It has a complicated γ ray spectrum with an average energy of 0.38 MeV. -> It required less shielding for personnel protection. </li></ul><ul><li>It has the disadvantage of a short half-life (73.8 days) </li></ul><ul><li>It is fabricated in the form of thin flexible wires which can be cut to desired lengths </li></ul>
  9. 11. Radioactive sources Iodine-125 <ul><li>Widely used for permanent implants. </li></ul><ul><li>Longer half-life: 59.4 days (convenient for storage) </li></ul><ul><li>Low photon energy (0.028MeV) -> less shielding. </li></ul><ul><li>Disadvantages: dosimetry of 125 I is much more complex. </li></ul>
  10. 12. Brachytherapy Permanently Implanted 0.19G/h 17 22keV 13 Pd 0.07G/h 59.6 28keV 125 I 1.07G/h 2.70 412keV 198 Au 0.75G/h 3.83 1.2MeV 222 Rn Dose Rate T1/2 Energy Source
  11. 13. Radioactive sources <ul><li>ICRU38 </li></ul><ul><li>LDR sources: 0.4-2 Gy/hr ( 137 Cs) </li></ul><ul><li>HDR sources: ≥ 12 Gy/hr ( 60 Co, 192 Ir) </li></ul><ul><li>226 Ra  leakage Radon gas. </li></ul><ul><li>137 Cs better than 226 Ra  less shielding and microsphere form with leakage gas. </li></ul><ul><li>137 Cs better than 60 Co  less shielding and cheap. </li></ul><ul><li>192 Ir better than 137 Cs  lower energy require less shielding for personnal protection and higher specific activity. </li></ul><ul><li>103 Pd better than 198 Au and 125 I  less shielding and biologic advantage . </li></ul>
  12. 14. Radioactive sources <ul><li>Short treatment times and minimal radiation protection problems . </li></ul><ul><li>Possibility of optimizing dose distribution by altering the dwell times of the source at different </li></ul><ul><li>Longer treatment times allow for leisurely review of and potential modifications to the treatment . </li></ul><ul><li>Plan prior to the delivery of a significant portion of treatment. </li></ul><ul><li>Favorable dose-rate effect on repair of normal tissues . </li></ul><ul><li>Infrequent replacement and calibration of sources because of long isotope half-life. </li></ul>Physical <ul><li>Maintain position of the sources during the brief treatment. </li></ul><ul><li>Patient preparation. </li></ul><ul><li>No specialized nursing. </li></ul><ul><li>Ability to treat great patient loads. </li></ul><ul><li>Improves chances of atching tumors in sensitive phase of cell cycle. </li></ul>Clinical <ul><li>No long term confinement to bed . </li></ul><ul><li>No indwelling bladder catheters. </li></ul><ul><li>Not labeled “radiation risk zone” to relative, visitors, and staff. </li></ul><ul><li>Avoid several anesthesias. </li></ul><ul><li>Long history of use. </li></ul><ul><li>Ability to predict rate of late complications </li></ul>Patient High Dose Rate (HDR) Low Dose Rate (LDR)
  13. 17. Brachytherapy and GYN Malignancy
  14. 18. Reference point from which lymph node position were measured on lymphoangiograms and the range of location Int. J Radiat Oncol Biol Phys 34:167-172, 1996
  15. 19. Distribution of pelvic node metastases in patients with Ib-IIa cervical cancer Gynecol Oncol 62:19-24, 1996 Tumor size <=4 cm Local advanced tumor
  16. 20. External beam radiotherapy for GYN Malignancy
  17. 21. Pelvic irradiation portal in cervical cancer 4-field box technique
  18. 22. Pelvic irradiation portal in cervical cancer 4-field box technique
  19. 24. Combination of external beam pelvic irradiation and intracavitary brachytherapy (ICRT)
  20. 25. Brachytherapy in definitive radiotherapy of cervical cancer (Intracavity radiotherapy, ICRT)
  21. 26. Intracavitary Radiotherapy (ICRT)
  22. 30. Applicator of ICRT
  23. 33. Intracavitary insertion (ICRT)
  24. 40. Postoperative brachytherapy (Intravaginal radiotherapy)
  25. 41. Intravaginal radiotherapy (IVRT)
  26. 44. Female urethral cancer
  27. 46. Endometrial cancer

×